This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Besaratinia, A. Articles by Pfeifer, G. P. Search for Related Content PubMed PubMed Citation Articles by Besaratinia, A. Articles by Pfeifer, G. P.

Mutational Signature of the Proximate Bladder Carcinogen N-Hydroxy-4-acetylaminobiphenyl

Inconsistency with the p53 Mutational Spectrum in Bladder Cancer¹

Department of Biology, Beckman Research Institute of the City of Hope, Duarte, California 91010

We studied the mutagenicity of the proximate bladder carcinogen, N-hydroxy-4-acetylaminobiphenyl (N-OH-AABP) in embryonic fibroblasts of the Big Blue mouse. Treatment of these cells with increasing concentrations of N-OH-AABP for 24 h resulted in a dose-dependent increase in mutation frequency of the cII transgene up to 12.8-fold over the background. Single base substitutions comprised 86% of the N-OH-AABP-induced mutations and 74% of the spontaneous cII mutations (sequenced number of mutant plaques, 141 and 145, respectively). Of these, 63 and 36%, respectively, occurred at guanine residues along the cII gene. Whereas G to T transversions predominated in the induced cII mutations (47%), insertion was the most spontaneously derived cII mutation (19%). Mapping of N-OH-AABP-induced DNA adducts along the cII gene by terminal transferase-dependent PCR showed the formation of DNA adducts at specific nucleotide positions. Five preferential DNA adduction sites were established, of which four were major mutation sites for N-OH-AABP, especially for G to T transversions. This unique mutational signature of N-OH-AABP in the cII gene was, however, in sharp contrast with the mutational spectrum of the p53 gene in human bladder cancer. G to A transitions are the dominant type of p53 mutations (53%), being also prevalent in almost all of its five mutational hotspots (codons 175, 248, 273, 280, and 285). In addition, the majority of mutations in three of these hotspots (codons 175, 248, and 273) are at a methylated CpG site, whereas in the cII gene neither the preferential N-OH-AABP DNA adduction sites nor the induced mutational hotspots are biased toward methylated CpG dinucleotides. We conclude that N-OH-AABP leaves a characteristic mutational signature in the cII transgene, which is consistent with its preferential DNA adduction profile. However, the pattern of mutation induced by N-OH-AABP in the cII gene is largely at odds with the mutational spectrum of the p53 gene in human bladder cancer.

This article has been cited by other articles:

				A. Besaratinia, S.-i. Kim, and G. P. Pfeifer Rapid repair of UVA-induced oxidized purines and persistence of UVB-induced dipyrimidine lesions determine the mutagenicity of sunlight in mouse cells FASEB J, July 1, 2008; 22(7): 2379 - 2392. [Abstract] [Full Text] [PDF]

				D.-H. Lee and G. P. Pfeifer Mutagenesis induced by the nitric oxide donor sodium nitroprusside in mouse cells Mutagenesis, January 1, 2007; 22(1): 63 - 67. [Abstract] [Full Text] [PDF]

				J. v. Brocke, H. H. Schmeiser, M. Reinbold, and M. Hollstein MEF immortalization to investigate the ins and outs of mutagenesis Carcinogenesis, November 1, 2006; 27(11): 2141 - 2147. [Abstract] [Full Text] [PDF]

				H. Wallerand, A. A. Bakkar, S. G. D. de Medina, J.-C. Pairon, Y.-C. Yang, D. Vordos, H. Bittard, S. Fauconnet, J.-C. Kouyoumdjian, M.-C. Jaurand, et al. Mutations in TP53, but not FGFR3, in urothelial cell carcinoma of the bladder are influenced by smoking: contribution of exogenous versus endogenous carcinogens Carcinogenesis, January 1, 2005; 26(1): 177 - 184. [Abstract] [Full Text] [PDF]

				J.-H. Yoon, A. Besaratinia, Z. Feng, M.-s. Tang, S. Amin, A. Luch, and G. P. Pfeifer DNA Damage, Repair, and Mutation Induction by (+)-Syn and (-)-Anti-Dibenzo[a,l]Pyrene-11,12-Diol-13,14-Epoxides in Mouse Cells Cancer Res., October 15, 2004; 64(20): 7321 - 7328. [Abstract] [Full Text] [PDF]

				A. Besaratinia and G. P. Pfeifer Genotoxicity of Acrylamide and Glycidamide J Natl Cancer Inst, July 7, 2004; 96(13): 1023 - 1029. [Abstract] [Full Text] [PDF]

				A. Besaratinia and G. P. Pfeifer Enhancement of the Mutagenicity of Benzo(a)pyrene Diol Epoxide by a Nonmutagenic Dose of Ultraviolet A Radiation Cancer Res., December 15, 2003; 63(24): 8708 - 8716. [Abstract] [Full Text] [PDF]

				L. E. Moore, A. H. Smith, C. Eng, S. DeVries, D. Kalman, V. Bhargava, K. Chew, C. Ferreccio, O. A. Rey, C. Hopenhayn, et al. P53 alterations in bladder tumors from arsenic and tobacco exposed patients Carcinogenesis, November 1, 2003; 24(11): 1785 - 1791. [Abstract] [Full Text] [PDF]

				A. Besaratinia and G. P. Pfeifer Weak Yet Distinct Mutagenicity of Acrylamide in Mammalian Cells J Natl Cancer Inst, June 18, 2003; 95(12): 889 - 896. [Abstract] [Full Text] [PDF]